Study on Fluoxetine’s Impact on Stroke Recovery

Introduction

Researchers have investigated the effects of fluoxetine, a selective serotonin reuptake inhibitor (SSRI), on the functional motor abilities of individuals undergoing stroke recovery. Stroke remains a significant health issue globally, with an estimated 6.5 million people affected by post-stroke disability, a condition that often leads to long-term impairment.

Background on Stroke Recovery

Post-stroke recovery typically involves addressing depression and other related factors. Fluoxetine has been considered for this purpose, alongside other SSRIs that may aid in recovery. Previous trials have indicated that fluoxetine could enhance motor skills and reduce depressive symptoms among stroke survivors. However, current stroke guidelines do not strongly endorse its use due to concerns over potential adverse reactions.

Study Design and Methodology

The FOCUS Trial Collaboration conducted the study, published in The Lancet. This double-blind randomized controlled trial was carried out across 103 hospitals in the United Kingdom. It involved adults diagnosed with acute strokes, with a total of 3,127 participants randomized into two groups: 1,564 received fluoxetine (20 mg), while 1,563 were given a placebo. Participants were assessed for functional ability at the six-month mark using the modified Rankin Scale (mRS), which evaluates disability levels in stroke patients.

Results

The analysis revealed no significant differences in functional ability between the fluoxetine group and the placebo group at the six-month assessment. However, those taking fluoxetine exhibited a lower likelihood of experiencing depression and negative mood compared to the placebo group. Nonetheless, there was an increased risk of bone fractures in the fluoxetine group. By the 12-month follow-up, the differences in mood and depressive symptoms between the two groups were no longer significant.

Conclusions

Overall, the study found no improvement in functional abilities for stroke survivors at either the six or twelve-month assessments. While fluoxetine showed some short-term benefits in reducing depression at the six-month mark, these effects diminished over time. Limitations of the study included a potential lack of representativeness of the patient sample and issues with medication adherence, which may have influenced the treatment’s effectiveness. Furthermore, the modified mRS, while relevant, may not be the most robust measure for assessing outcomes. Potential bias from face-to-face interactions with patients was also noted.

Future Research Directions

The findings of this study suggest that fluoxetine may not provide significant benefits for individuals recovering from strokes. Further research is warranted to explore whether fluoxetine could be more harmful than helpful in this context.

References

FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised controlled trial. The Lancet. 2018; 1–10. doi: http://dx.doi.org/10.1016/S0140-6736(18)32823-X

Written by

Olajumoke Marissa Ologundudu B.Sc. (Hons)